Bli medlem
Bli medlem

Du är här

2016-02-24

Xvivo Perfusion: XPS™ to be delivered to the first clinic in France

H?pital FOCH in Paris is the first clinic in France that has decided
to use XPS?. Delivery and installation of XPS? is estimated to take
place at the end of March 2016.

The clinic in Paris has more than 25 years' experience of lung
transplantation and is one of the leading lung transplant clinics in
France, with a well-reputed Ex Vivo Lung Perfusion (EVLP) program.

Under the leadership of Professor Alain Chapelier, the clinic in Paris
has carried out EVLP using the so-called manual STEEN Solution?
method. "We will now be able to continue to explore EVLP using XPS?
and STEEN Solution?," says Dr Edouard Sage, who is in charge of the
clinical EVLP program.

XPS? is the only CE-marked and FDA approved integrated system on the
market today which gives the user the flexibility to perform
evaluation of lungs before transplantation through a standardized and
simplified procedure. Use of XPS? has shown good clinical results at
18 clinics in the US, many of which are national leaders in their
field. Six XPS? contracts have now been signed by European clinics,
giving them access to the XPS? system for lung transplantation, and
the company notes continuing high interest for the XPS? in Europe.

"We are delighted that the FOCH clinic in Paris, which has great
experience of transplanting lungs after performing EVLP with STEEN
Solution? with good clinical results, is now moving on to a more
standardized and simplified EVLP using the XPS? system," says Magnus
Nilsson, CEO of XVIVO Perfusion.

February 24, 2016
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, +46 31 788 2150,
magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion's business, please refer to
the company's website, www.xvivoperfusion.com

The information was submitted for publication on February 24, 2016 at
8:30 a.m.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in the USA. The XVIVO share is listed on NASDAQ First North premier
and has the ticker symbol XVIVO. More information can be found on the
website www.xvivoperfusion.com. The Certified Adviser is Redeye,
www.redeye.se.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 G?teborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
-----------------------------------------------------------
http://news.cision.com/xvivo-perfusion/r/xps--to-be-delivered-to-the-fir...
http://mb.cision.com/Main/4567/9923639/481245.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.